Search clinical trials for: fluticasone propionate/salmeterol plus tiotropium bromide

Total 209 results

GlaxoSmithKline

Completed

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (SCO116572)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease (ESWT)

Pulmonary Disease, Chronic Obstructive

Canada, United States
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
Boehringer Ingelheim

Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Pulmonary Disease, Chronic Obstructive

Austria, Canada, France, Germany, Italy, Russian Federation, Sweden
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
Brigham and Women's Hospital
Massachusetts General Hospital; Baim Institute for Clinical Research

Terminated

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations (GABLE)

Asthma

United States
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Cardiovascular Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
Henan University of Traditional Chinese Medicine

Unknown

Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Novartis Pharmaceuticals

Completed

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (ARGON)

Asthma

Germany, India, Israel, Poland, Argentina, Russian Federation, Greece, Serbia, Turkey, Hungary, Mexico, Peru, Slovakia, Czechia, South Africa, Taiwan, Vietnam, Spain, Colombia, Chile
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder in COPD

Pulmonary Disease, Chronic Obstructive

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, South Africa, Sweden
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, Sweden
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

Pulmonary Disease, Chronic Obstructive
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Brigham and Women's Hospital

Completed

Replication of the INSPIRE Trial in Healthcare Claims Data

Chronic Obstructive Pulmonary Disease

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Asthma

Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russian Federation, Slovakia, South Africa, Spain, Turkey, United Kingdom
GlaxoSmithKline

Completed

Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Romania, Poland, Czechia
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
Dey

Completed

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Seoul National University Hospital

Completed

Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Taipei Veterans General Hospital, Taiwan
GlaxoSmithKline

Unknown

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

COPD

Taiwan
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) (TALC)

Asthma

United States
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Boehringer Ingelheim

Completed

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Denmark, France, South Africa, Austria, Belgium, Sweden
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
GlaxoSmithKline

Completed

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Asthma

United States, Russian Federation, Canada, Germany, Peru, Australia, Mexico, Chile, Costa Rica, Spain, Poland, Lithuania, Latvia
GlaxoSmithKline

Completed

Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.

Asthma

United Kingdom

3

Subscribe